The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone

Andreasen, 2005, Remission in schizophrenia: Proposed criteria and rationale for consensus, Am. J. Psychiatry, 162, 441, 10.1176/appi.ajp.162.3.441 Ascher-Svanum, 2005, Type of symptom remission and treatment outcomes in the long-term treatment of patients with schizophrenia, Neuropsychopharmacology, S112 Buchanan, 2005, A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia, Schizophr. Bull., 311, 5, 10.1093/schbul/sbi020 Carpenter, 2002, A new view of therapy for cognition in schizophrenia, Biol. Psychiatry, 51, 969, 10.1016/S0006-3223(02)01399-9 Cornblatt, 1989, The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients, Psychiatry Res., 29, 65, 10.1016/0165-1781(89)90188-1 Davidson, L., O'Connell, M., Tondora, J., Styron, T., Kangas, K., in press. The top ten concerns about recovery encountered in mental health system transformation. Psychiatr. Serv. Green, 1996, What are the functional consequences of neurocognitive deficits in schizophrenia?, Am. J. Psychiatry, 153, 321, 10.1176/ajp.153.3.321 Green, 1997, Does risperidone improve verbal working memory in treatment resistant schizophrenia?, Am. J. Psychiatry, 154, 799, 10.1176/ajp.154.6.799 Green, 2004, Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria., Biol. Psychiatry, 565, 301, 10.1016/j.biopsych.2004.06.023 Harvey, 2001, Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment, Am. J. Psychiatry, 158, 176, 10.1176/appi.ajp.158.2.176 Harvey, 2004, Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness, J. Clin. Psychiatry, 65, 361, 10.4088/JCP.v65n0312 Harvey, 2004, Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia, Schizophr. Res., 66, 101, 10.1016/j.schres.2003.07.009 Harvey, 2006, The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements, Psychopharmacology (Berl), 187, 356, 10.1007/s00213-006-0432-1 Harvey, P.D., Bowie, C.R., Loebel, A., in press. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a 6-month, randomized, double-blind comparison of ziprasidone vs. olanzapine. J. Neuropsychiatry Clin. Neurosci. Heaton, 1993 Kay, 1991 Keefe, 2006, Baseline neurocognitive deficits in the CATIE Schizophrenia Trial, Neuropsychopharmacology, 31, 2033, 10.1038/sj.npp.1301072 Lasser, 2005, Remission in schizophrenia: data from a one-year study of risperidone long-acting injectible, Schizophr. Res., 77, 215, 10.1016/j.schres.2005.03.006 Leucht, 2005, What does the PANSS mean?, Schizophr. Res., 79, 231, 10.1016/j.schres.2005.04.008 Liberman, 2005, Sustained remission of schizophrenia, Am. J. Psychiatry, 162, 173, 10.1176/appi.ajp.162.9.1763 Liberman, 2002, Operational criteria and factors related to recovery from schizophrenia, Int. Rev. Psychiatry, 14, 256, 10.1080/0954026021000016905 Lieberman, 2005, Effectiveness of antipsychotic drugs in patients with schizophrenia, N. Engl. J. Med., 353, 1209, 10.1056/NEJMoa051688 McGurk, 2005, Cognitive training and supported employment for persons with severe mental illness: one-year results from a randomized controlled trial, Schizophr. Bull., 31, 898, 10.1093/schbul/sbi037 Montgomery, 1979, A new depression scale designed to be sensitive to change, Br. J. Psychiatry, 134, 382, 10.1192/bjp.134.4.382 Nierenberg, 2001, Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression, J. Clin. Psychiatry, 62, 5 Ragins, 2005, Should the CATIE study be a wakeup call?, Psychiatr. Serv., 56, 1489, 10.1176/appi.ps.56.12.1489 Reitan, 1993 Robinson, 2004, Symptomatic and functional improvement from a first episode of schizophrenia or schizoaffective disorder, Am. J. Psychiatry, 161, 473, 10.1176/appi.ajp.161.3.473 Spreen, 1998 Weiden, 2003, Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia, J. Clin. Psychiatry, 64, 580, 10.4088/JCP.v64n0514 Wexler, 2005, Cognitive remediation and vocational rehabilitation for schizophrenia, Schizophr. Bull., 31, 931, 10.1093/schbul/sbi038 Woodward, N.D., Purdon, S.E., Meltzer, H.Y., Zald, D.H. A meta–analysis of neuropsychological change to change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8, 457–472.